Salim Syed
Stock Analyst at Mizuho
(1.98)
# 2,999
Out of 4,761 analysts
76
Total ratings
35.59%
Success rate
-4.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $11.33 | +94.17% | 5 | Nov 21, 2024 | |
| NKTX Nkarta | Maintains: Outperform | $20 → $16 | $2.15 | +644.19% | 7 | Nov 21, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $90 → $100 | $110.03 | -9.12% | 6 | Nov 21, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $99 → $103 | $51.12 | +101.49% | 6 | Nov 21, 2024 | |
| BIIB Biogen | Maintains: Outperform | $251 → $207 | $137.08 | +51.01% | 15 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $82.47 | +97.65% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $7.52 | +139.36% | 4 | Aug 16, 2024 | |
| AMGN Amgen | Maintains: Neutral | $223 → $235 | $297.93 | -21.12% | 7 | May 9, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $21.47 | +58.36% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $50.43 | +96.31% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $36.81 | +44.00% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $2.05 | +192.68% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.10 | +1,809.09% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $12.75 | +182.35% | 1 | Nov 16, 2022 |
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $11.33
Upside: +94.17%
Nkarta
Nov 21, 2024
Maintains: Outperform
Price Target: $20 → $16
Current: $2.15
Upside: +644.19%
Gilead Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $90 → $100
Current: $110.03
Upside: -9.12%
Cytokinetics
Nov 21, 2024
Maintains: Outperform
Price Target: $99 → $103
Current: $51.12
Upside: +101.49%
Biogen
Nov 21, 2024
Maintains: Outperform
Price Target: $251 → $207
Current: $137.08
Upside: +51.01%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $82.47
Upside: +97.65%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $7.52
Upside: +139.36%
Amgen
May 9, 2024
Maintains: Neutral
Price Target: $223 → $235
Current: $297.93
Upside: -21.12%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $21.47
Upside: +58.36%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $50.43
Upside: +96.31%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $36.81
Upside: +44.00%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $2.05
Upside: +192.68%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.10
Upside: +1,809.09%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $12.75
Upside: +182.35%